The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq ends lower as oil prices surge ahead of earnings, economic data
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| Regeneron (NASDAQ: REGN) | Delayed: 758.83 +12.29 (1.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $746.54 | 52 Week High | $592.36 | |||
| Open | $748.67 | 52 Week Low | $325.35 | |||
| Day High | $768.66 | P/E | 199.17 | |||
| Day Low | $744.96 | EPS | $3.81 | |||
| Volume | 433,796 | |||||
